(A) | |
---|---|
EFRT patient characteristics | |
Age (years) | |
Mean (SD) | 54.8 (13.8) |
Median (range) | 52 (35–85) |
Primary cervical cancer | 32 (94%) |
Post-operative recurrent cervical cancer | 1 (3%) |
Primary endometrial cancer | 1 (3%) |
Medical history affecting renal function | |
None | 25 (74%) |
Hypertension | 5 (15%) |
Hypercholesterolemia | 1 (3%) |
Diabetes and hypercholesterolemia | 1 (3%) |
Diabetes, hypertension, and hypercholesterolemia | 1 (3%) |
Nephrotic syndrome | 1 (3%) |
Pre-treatment baseline creatinine clearance | |
Mean (SD) | 86.6 mL/min (20.5) |
Median (range) | 84 mL/min (57.8–149.8) |
Histology | |
Squamous cell carcinoma | 28 (82%) |
Adenocarcinoma | 6 (18%) |
Para-aortic node positive on 18F-FDG-PET/CT | |
Yes | 32 (94%) |
No | 2 (6%) |
External beam radiotherapy | |
Box field EFRT | 13 (38%) |
Coplanar EF-IMRT | 15 (44%) |
Non-coplanar EF-IMRT | 6 (18%) |
EFRT dose (Gy) | |
Median (range) | 55.8 (55.8–59.4) |
(B) | |
---|---|
WPRT patient characteristics | |
Age (years) | |
Mean (SD) | 57.1 (12.9) |
Median (range) | 56 (31–85) |
Primary cervical cancer | 54 (84%) |
Post-operative cervical cancer | 10 (16%) |
Medical history affecting renal function | |
None | 49 (77%) |
Hypertension | 6 (9%) |
Hypercholesterolemia | 5 (8%) |
Diabetes and hypertension | 2 (3%) |
Diabetes | 1 (2%) |
Hypertension and hypercholesterolemia | 1 (2%) |
Pre-treatment baseline creatinine clearance | |
Mean (SD) | 83.4 mL/min (19.1) |
Median (range) | 80.8 mL/min (47.6–152.1) |